Anti-VEGFA antibody

• IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody (AB183100)

Immunohistochemical analysis of paraffin embedded Human liver cancer tissue labeling VEGFA with ab183100 at 1/25 dilution. Image on the right is treated with the synthetic peptide.

• WB

Supplier Data

Western blot - Anti-VEGFA antibody (AB183100)

All lanes:

Western blot - Anti-VEGFA antibody (ab183100) at 1/1000 dilution

Lane 1:

HeLa (human epithelial cell line from cervix adenocarcinoma) cell lysate at 30 µg

Lane 2:

HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) cell lysate at 30 µg

Lane 3:

HepG2 (human liver hepatocellular carcinoma cell line) cell lysate at 30 µg

Lane 4:

HT29 cell lysate at 30 µg

Lane 5:

MDA-MB-231 (human breast adenocarcinoma cell line) cell lysate at 30 µg

Lane 6:

A549 (human lung carcinoma cell line) cell lysate at 30 µg

Lane 7:

SK-OV-3 (human ovarian cancer cell line) cell lysate at 30 µg

Secondary

All lanes:

Goat anti Rabbit IgG - H&L (HRP) at 1/100 dilution

Predicted band size: 27 kDa

true

Exposure time: 2min

• WB

Supplier Data

Western blot - Anti-VEGFA antibody (AB183100)

All lanes:

Western blot - Anti-VEGFA antibody (ab183100) at 1/450 dilution

Lane 1:

Hela cell lysate at 40 µg

Lane 2:

Jurkat cell lysate at 40 µg

Lane 3:

293T cell lysate at 40 µg

Lane 4:

231 cell lysate at 40 µg

Secondary

All lanes:

Goat anti Rabbit IgG - H&L (HRP) at 1/10000 dilution

Predicted band size: 27 kDa

false

Exposure time: 2min

• WB

CiteAb

Western blot - Anti-VEGFA antibody (AB183100)

VEGFA western blot using anti-VEGFA antibody ab183100. Publication image and figure legend from Wei, X., Zhang, K., et al., 2018, BMC Cancer, PubMed 29843634.

ab183100 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab183100 please see the product overview.

Widespread changes of gene expressions and critical pathways in human lung adenocarcinoma cells A549 with GMDS knockdown. a Heatmap containing 739 differentially expressed genes in human lung adenocarcinoma cell line A549 infected with lentivirus expressing either Scr-shRNA (purple) or GMDS-shRNA (red) with the criteria p < 0.05 and ▏fold change ▏ > 1.5. Genes and samples were listed in rows and columns, respectively. A colour standard for normalized expression data was shown at the bottom of the microarray heatmap (green represents downregulated genes while red represents upregulated genes). b Gene expression changes identified in microarray were confirmed using real-time quantitative PCR for selected genes CASP8, MAP3K7, CDKN1A, FAS, JUN, DDIT3, VEGFA, SKA1 and MAD2L1 in human lung adenocarcinoma cell line A549 infected with lentivirus expressing either Scr-shRNA or GMDS-shRNA. Histogram shown here was one out of three independent experiments (p < 0.01) and normalized to GAPDH. c Protein level of FAS, VEGFA, DDIT3, JUN and CDKN1A in human human lung adenocarcinoma cell line A549 infected with lentivirus expressing either Scr-shRNA or GMDS-shRNA. GAPDH was used as internal control. d Caspase3/7 activity analysis in A549 cells and H1299 cells infected with lentivirus expressing either Scr-shRNA or GMDS-shRNA. Data shown are the mean ± SEM of caspase3/7 activity from three independent experiments (**, p < 0.01)

false